Clinical Trials Browser

Not yet recruiting × Paclitaxel × Gynecologic × Clear all

NCT07286331 2026-03-11

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)

Phase 3 Not yet recruiting

Endometrial Neoplasms

NCT07418749 2026-02-18

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

Phase 3 Not yet recruiting

Uterine Cervical Neoplasms

NCT07407452 2026-02-12

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

Phase 2 Not yet recruiting

Ovarian Neoplasms

NCT07401654 2026-02-10

The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression

Phase 2 Not yet recruiting

Ovarian Neoplasms

NCT07286266 2025-12-16

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Phase 3 Not yet recruiting

Ovarian Neoplasms

NCT07265739 2025-12-11

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer

Phase 2 Not yet recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06980545 2025-05-20

Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer

Phase 3 Not yet recruiting

Stage III and IV Ovarian Cancer

NCT06870565 2025-03-17

Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma

Phase 3 Not yet recruiting

Uterine Cervical Neoplasms

NCT06867562 2025-03-10

Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer

Phase 3 Not yet recruiting

Platinum-Resistant Primary Peritoneal Carcinoma

NCT06751485 2024-12-31

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

Phase 3 Not yet recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06751277 2024-12-27

QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer

Phase 2 Not yet recruiting

Recurrence, Endometrial Neoplasms

NCT06620029 2024-10-01

BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer

Phase 1/2 Not yet recruiting

Ovarian Neoplasms, Endometrial Neoplasms

NCT06102252 2024-08-06

Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma

Phase NA Not yet recruiting

Endometrial Neoplasms

NCT05921149 2024-05-07

Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer

Phase NA Not yet recruiting

Ovarian Neoplasms

NCT06363708 2024-04-12

Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer

Phase NA Not yet recruiting

Neoplasms, Endometrial Neoplasms

NCT06297811 2024-03-07

Myeloprotection With Trilaciclib in Pan-cancer Population

Phase 2 Not yet recruiting

BreastGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT06066216 2024-01-23

Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer

Phase 2 Not yet recruiting

Endometrial Neoplasms

NCT06149767 2023-11-29

Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms

NCT05794659 2023-07-20

Cornerstone4

Phase 2 Not yet recruiting

Advanced Ovarian Cancer

NCT05489848 2022-08-05

Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation

Phase 2/3 Not yet recruiting

Endometrial Neoplasms